Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Hit With Slew Of Suits As Firms Fight For Market Advantage

Executive Summary

At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.


Related Content

FDA Biosimilar Guidances Stir Innovator Worries About BLA Exclusivity, Trade Secrets
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Imports Of Lethal Injection Drug A Law Enforcement Issue, FDA Says
Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA
FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
No Appeal: Eloxatin Decision Gives District Courts Primacy On 30-Month Stays
Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals
ANDA Exclusivity Protected From Patent Delisting Under Appeals Court Ruling
FDA’s Office of Chief Counsel Is Growing Its Ranks As It Amends Its Act


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts